Quinupristin/Dalfopristin

Quinupristin/Dalfopristin is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

  • Quinupristin/dalfopristin (7.5 mg/kg IV q8h) is the first FDA-approved drug in the streptogramin class.
  • This agent has activity against antibiotic-resistant gram-positive organisms, especially VRE, MRSA, and antibiotic-resistant strains of Streptococcus pneumoniae. It has some activity against gram-negative upper respiratory pathogens (Haemophilus and Moraxella) and anaerobes, but more appropriate antibiotics are available to treat these infections. Quinupristin/dalfopristin is bacteriostatic for enterococci and can be used for treatment of serious infections with VRE (only E. faecium because it is inactive against E. faecalis).

-- To view the remaining sections of this topic, please or --

General Principles

  • Quinupristin/dalfopristin (7.5 mg/kg IV q8h) is the first FDA-approved drug in the streptogramin class.
  • This agent has activity against antibiotic-resistant gram-positive organisms, especially VRE, MRSA, and antibiotic-resistant strains of Streptococcus pneumoniae. It has some activity against gram-negative upper respiratory pathogens (Haemophilus and Moraxella) and anaerobes, but more appropriate antibiotics are available to treat these infections. Quinupristin/dalfopristin is bacteriostatic for enterococci and can be used for treatment of serious infections with VRE (only E. faecium because it is inactive against E. faecalis).

There's more to see -- the rest of this entry is available only to subscribers.